Brandi Roberts Biography and Net Worth

Ms. Roberts has more than 25 years of financial leadership experience within the life sciences industry. Prior to joining Definium, she served as CFO and Executive Vice President of Longboard Pharmaceuticals, where she helped lead the company through its IPO, multiple financings, and ultimately, its $2.6 billion acquisition by Lundbeck in 2024. Throughout her career, Ms. Roberts has played pivotal roles in scaling operations, supporting clinical development, and managing investor relations with leading investors, funds, and analysts. She has held CFO roles at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, and senior finance positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts received her MBA from the University of San Diego and her B.S. degree in business administration in Accounting and Finance from the University of Arizona. She is a Certified Public Accountant in the State of California and currently serves on the board of advisors for Life Science Cares San Diego and the board for the Association of Bioscience Financial Officers Southwest chapter.

What is Brandi Roberts' net worth?: The estimated net worth of Brandi Roberts is at least $9.49 million as of June 25th, 2026. Roberts owns 209,487 shares of Definium Therapeutics stock worth more than $9,485,571 as of June 29th. This net worth evaluation does not reflect any other investments that Roberts may own. Learn More about Brandi Roberts' net worth.
How do I contact Brandi Roberts?: The corporate mailing address for Roberts and other Definium Therapeutics executives is One World Trade Center Suite 8500 New York, NY 10007 United States. Definium Therapeutics can also be reached via phone at 212 220 6633 and via email at [email protected]. Learn More on Brandi Roberts' contact information.
Has Brandi Roberts been buying or selling shares of Definium Therapeutics?: During the last quarter, Brandi Roberts has sold $135,675.39 of Definium Therapeutics stock. Most recently, Brandi Roberts sold 3,013 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a transaction totalling $135,675.39. Following the completion of the sale, the chief financial officer now directly owns 209,487 shares of the company's stock, valued at $9,433,199.61. Learn More on Brandi Roberts' trading history.
Who are Definium Therapeutics' active insiders?: Definium Therapeutics' insider roster includes Robert Barrow (Chief Executive Officer and Board Director), Schond Greenway (CFO), David Gryska (Director), Dan Karlin (Insider), Daniel Karlin (Insider), Carrie Liao (CAO), Brandi Roberts (CFO), and Mark Sullivan (Insider). Learn More on Definium Therapeutics' active insiders.
Are insiders buying or selling shares of Definium Therapeutics?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 135,542 shares worth more than $3,164,324.76. The most recent insider tranaction occured on June, 25th when insider Mark Sullivan sold 13,008 shares worth more than $585,750.24. Insiders at Definium Therapeutics own 2.4% of the company. Learn More about insider trades at Definium Therapeutics.
Information on this page was last updated on 6/25/2026.

Brandi Roberts Insider Trading History at Definium Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/25/2026	Sell	3,013	$45.03	$135,675.39	209,487

Brandi Roberts Buying and Selling Activity at Definium Therapeutics

Definium Therapeutics Company Overview

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Today's Range

Now: $46.59

$44.25

$47.20

50 Day Range

MA: $24.59

$20.02

$44.95

2 Week Range

Now: $46.59

$6.40

$47.20

Volume

3,298,210 shs

Average Volume

2,294,033 shs

Market Capitalization

$4.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37